



FOR IMMEDIATE RELEASE

NuSep Board Changes

Sydney, Australia 29th October 2013–NuSep Holdings Ltd (ASX:NSP). The Board of NuSep is pleased to announce that Ms Alison Coutts will, subject to shareholder approval, join the Board of NuSep effective from the close of the AGM on 29th November 2013. This is following on from the announcement to refresh the Board made at the 2012 AGM and again in the August 2013 shareholder newsletter.

Mr John Manus, the current Chairman of NuSep, and Dr Hari Nair, NuSep's Deputy Chairman, will step down from the NuSep Board at the conclusion of the AGM on 29th November 2013 to concentrate on developing PrIME Biologics in Singapore. Finally, as part of this Board renewal Mr Clifford Eu will also step down at the end of the AGM on 29th November 2013.

It is expected that Ms Coutts will take on the role of Non -Executive Chairman effective from the conclusion of the AGM on 29th November 2013. A copy of Ms Coutts CV is outlined below as part of this announcement.

This refreshment of the Board will allow NuSep to concentrate on developing and commercialising its many applications of the PrIME technology now that the plasma application funding is in train.

Dr Nair and Mr Manus will concentrate on developing PrIME into a successful plasma fractionation organisation with an immediate focus on achieving cGMP approval for its Singapore facility. **It is difficult to underline the importance of regulatory approval as it validates the PrIME Technology and opens up a multitude of other industrial and commercial applications for NuSep.** Furthermore, subject to shareholder approval, all NuSep shareholders will own a prorata shareholding in PrIME Biologics post the demerger which is due to occur in the first quarter of 2014.

Dr Nair will continue to assist the board with the scientific innovation and research within NuSep under a consultancy agreement.

Mr Eu is stepping down now that the PrIME Biologics funding is moving forward. The Chairman, Mr John Manus, said that 'Mr Eu has made a significant contribution to the Board deliberations on the PrIME Funding and we wish him all the best in his future endeavours.'

Ms Coutts appointment will allow NuSep to bring on the new skills necessary to develop the next commercial applications of the PrIME Technology including sperm separation for IVF and the diagnostic dengue application. To this end it is expected that further Board announcements will be made as Ms Coutts, in conjunction with the remaining Board, bring in relevant talent to refocus and align the Board to the goals of the Company.

NuSep Holdings Ltd
30 Richmond Rd
Homebush NSW 2140

Postal Address
P.O. Box 2202
Homebush West NSW 2140

Contact Details
Telephone +61 2 8415 7300
Facsimile +61 2 8415 7399

Email info@nusep.com
Web www.nusep.com
ABN 33 120 047 556

Ms Alison Coutts B.E (Chem), MBA, Grad Dip Biotech

Independent Non-Executive Director

Ms Coutts has extensive experience across a number of industry sectors and disciplines. This includes international engineering project management with Bechtel Corporation in the UK, USA and NZ, strategy consulting, management training and organisational structuring with Boston Consulting Group, and executive search with Egon Zehnder. Ms Coutts is formerly Chair of CSIRO's Health Sector Advisory Council and was a founder and director of eG Capital, which was a preeminent financial advisory firm in the Australian Life Sciences sector. Most recently Ms Coutts has focused on advising and raising capital for a number of emerging technology companies. In addition she has founded a clinical stage drug development company and two medical device companies, which she chairs. Ms Coutts is an independent non-executive director of DataDot technology (ASX: DDT).

For more information please contact:

Contact:
Prakash Patel
Managing Director
+61 2 8415 7300
prakash.patel@nusep.com

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. The company has offices in both Sydney Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques based on its PrIME¹ technology. The PrIME technology has produced a number of world firsts including the world's first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep's world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

-  **Gels** – NuSep manufactures and sells precast gels including the innovative nUView Gels, which can be visualised 2 minutes after use.
-  **Separation Instruments** – NuSep has developed two unique biological separation instruments. The ProteomeSep can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF.
-  **Biological Products** – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

¹ PrIME stands for **P**reparative **I**solation by **M**embrane **E**lectrophoresis

For more information about NuSep please visit the company's website www.NuSep.com

About PrIME Biologics Pte Ltd

PrIME Biologics is a Singapore based biotech company that has developed a disposable therapeutic plasma manufacturing process based on NuSep's PrIME Technology. PrIME Biologics process is based on the **P**reparative **I**solation by **M**embrane **E**lectrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is 'electronically' driven membrane fractionation.

The PrIME process increases product yields to over 90% relative to the existing process 50% while increasing product safety. The PrIME has been shown to remove virus, bacteria, endotoxins and prions which cause 'Mad Cow Disease'. Further, PrIME Biologics process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.

The initial application for the PrIME process will be the *Currently Unprocessable Plasma* which represents approximately 50% of all the plasma collected in many Asian countries.